- cafead   Jul 25, 2024 at 10:22: PM
via Three months after bagging FDA approval, Pfizer’s hemophilia B gene therapy has been cleared to expand its reach across the pond.
The therapy, which is branded as Beqvez in the U.S., received a conditional marketing authorization from the European Commission under the moniker Durveqtix.
article source
The therapy, which is branded as Beqvez in the U.S., received a conditional marketing authorization from the European Commission under the moniker Durveqtix.
article source